Teva to Develop Unique Wearable Tech and Machine Learning Platform for Continuous …

Platform aims to enhance understanding of disease progression and impact of treatment JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announces a collaboration with Intel Corporation to develop a unique wearable device and machine learning platform for use in Huntington disease (HD). This platform will continuously monitor and analyze key symptoms that impact daily living, in an effort to better understand disease progression and improve treatment evaluation. Teva, working in collaboration with Intel, will deploy this novel technology platform for the first time in a sub-study within the ongoing Phase 2 Open-Pride HD Study. As part of this, patients will be asked to use a smartphone and wear a smartwatch equipped with sensing technology that will continuously measure their general functioning and movement. These data will be wirelessly streamed‚Ķ


Link to Full Article: Teva to Develop Unique Wearable Tech and Machine Learning Platform for Continuous …